M&A / Property
Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals

TLRY · Price
Executive Summary
- Tilray Pharma’s European distribution arm, CC Pharma, entered a strategic agreement with UK‑based Smartway Pharmaceuticals to expand parallel import and specialist pharmaceutical supply in the United Kingdom.
- The partnership leverages Smartway’s national distribution network and CC Pharma’s procurement and GMP capabilities, targeting the roughly £1 billion UK market for these product categories.
- Both parties will explore further collaborative opportunities, reinforcing Tilray’s broader European medical expansion strategy and positioning its medicinal cannabis products within the UK health system.
Key Details
- Agreement Scope: Joint support of parallel import and specialist pharmaceutical supply across the UK; combined use of Smartway’s distribution infrastructure and CC Pharma’s procurement/GMP capacity.
- Market Opportunity: UK market for these pharmaceutical categories estimated at ~£1 billion.
- Strategic Rationale: Enhances Tilray’s ability to broaden access to medicinal products, improve supply reliability, and embed its cannabis medicines into the UK health system.
- Relationship History: CC Pharma and Smartway have collaborated since 2009; this agreement represents the next phase of that partnership.
- Future Collaboration: Both companies will assess additional opportunities for broader cooperation over time.
Notable Quotes
- “The UK is a priority market within Tilray’s international medical strategy…this agreement strengthens our ability to broaden access to medicinal products…” – Rajnish Ohri, President, International, Tilray Brands.
- “This agreement represents an important step forward in expanding our pharmaceutical distribution activities into the UK.” – Mathias Bossen, Managing Director, CC Pharma.
- “Our focus is always on patients and outcomes…this agreement supports continuity and expansion of access to medicines across UK healthcare.” – Josh Cocklin, Chief Executive, Smartway Pharmaceuticals.
More from TILRAY BRANDS, INC. J
Jun 29, 2026 · 17:09